0 €

Gerbu Adjuvant

adjuvant [from Latin adjuvāns, present participle of adjuvāre]
1. A pharmacological agent added to a drug to increase or aid its effect.
2. An immunological agent that increases the antigenic response.
 Dr. N. Grubhofer


In 1991 Dr. Nikolaus Grubhofer started research to make his vision come true. He decided to develop a better adjuvant, which meant: match Freund's adjuvant as the yardstick of efficiency, make it perfectly biotolerable, remove the emulsion handling problem, maintain a reasonable price level and get it patented and licensed. Many data and formulations have become available as the result of the 50 years of scientific work following Freund1. The trouble with all this work was that it was done nearly exclusively with mice and was of very limited use with larger animals, which were the necessary models for veterinary and human vaccination.

In 2001 the GERBU Adjuvant (GAD) formulations basically were ready2: A microsuspension of cationized lipid solid particles in water combined with GMDP and other synergists. They could be simply mixed with the antigen solution and were as effective as Freund's FCA, also in other species such as sheep, goats, cattle and humans - but devoid of its drawbacks: They were completely biocompatible and easy to use, suitable for a wide range of applications3,4,5 and potentially for licensing in pharmaceutical use.

After more than 10 years of development and field tests, GAD have emerged as the only efficient, biocompatible, convenient and economical successors of adjuvants as Freund's, Montanide or Alumina.

GERBU ADJUVANT - A powerful potentiator of cellular and humoral immune response with long-term protecting effect. Very stable and biocompatible. Just mix with antigen and inject.


Laboratory Adjuvants
For research and lab-scale antibody production.
Vaccine Adjuvants
For immunization and field application.

Adjuvant Monoclonals

Specifically for monoclonal antibody production. Specially developed formulation for best yield of fused clones in mice6. Successfully used for hybridoma technique and cancer immunotherapy.

Adjuvant Fama

For treating large, particularly sensitive animals such as horses and camels, potentially also for human pharmaceutical use. High API concentration for small injection volumes. Free from Saponins.

Adjuvant Polyclonals

Emerged out of the classic formulas LQ/10/100. Universal lab quality for antibody production. Extremely robust formula for less sensitive animals like rats, rabbits, chicken, goats. Still very mild, no local reactions.7

Adjuvant Veterinary

For large scale vaccination of cattle.

New “incomplete” formula, best efficiency and cost-benefit ratio.

Please inquire.



enlarge picture

3 Synergistic Factors at work:

Factor 1: Cationic Microparticles in a colloidal suspension replace the classic water-in-oil emulsion. They bind the antigen and immediately carry it to the lymphocytes for phagocytosis. There is no local depot and of course no granuloma. Their composition makes them immunostimulating, they are slowly biodegradable and non-irritant.

Factor 2: GMDP8 the adjuvant glycopeptide derived from L. bulgaricus cell walls. GMDP replaces the mycobacteria in FCA. It is completely devoid of local reactions upon injection. It is pyrogenic and somnogenic9 in larger doses. Induces T-cell response and long-lasting cellular immunity.

Factor 3: Immunomodulators Cimetidine, a histamine antagonist has been found to generally enhance immune response. Saponin, an efficient unspecific stimulator of the immune system.


  1. GRUBHOFER, N. (2008). Vaccine Adjuvants revisited. The Open Veterinary Science Journal, 2, 63-67<
  2. GRUBHOFER, N. (1995). An adjuvant formulation based on GMDP and DDA synergist. Immunology Letters 44: 19-24
  3. PARDON, E., LAEREMANS, T., TRIEST, S., RASMUSSEN, S. G. F., WOHLKÖNIG, A., RUF, A., MUYLDERMANS, S., HOL, W.G.J., KOBILKA, B.K., & STEYAERT, J. (2014). A general protocol for the generation of Nanobodies for structural biology. Nature Protocols 9, 674–693.
  4. KATEREGGA, J., LUBEGA, G.W., LINDBLAD, E.B., AUTHIÉ, E., COETZER, T.H.T. & BOULANGÉ, A.F.V. (2012). Effect of adjuvants on the humoral immune response to congopain in mice and cattle. BMC Veterinary Research, 8:63.
  5. MARGOS, M.1, GOTTSTEIN, B. (2010). Gerbu adjuvant modulates the immune response and thus the course of infection in C56BL/6 mice immunised with Echinococcus multilocularis rec14-3-3 protein.
    Parasitology Research. Aug;107 (3) :623-9.
  6. FERBER, P.C., OSSENE, P., HOMBERGER, F.R., & FISCHER, R.W. (1999). The generation of monoclonal antibodies in mice: influence of adjuvants on the immune response, fusion efficiency and distress. Laboratory Animals, 33.
  7. Bundesamt für Veterinärwesen (2017). Fachgerechte und tierschutzkonforme Antikörperproduktion in Kaninchen, Hühnern und Labornagetieren. In: Fachinformation 3.04
  8. IVANOV, V.T., ANDRONOVA, T.M., BEZRUKOV, M.V., RAR, V.A., MAKAROV, E.A., KOZMIN, S.A., ASTAPOVA, M. V., BARKOVA, T.I., & NESMEYANOV, V.A. (1987). Structure, design, and synthesis of immunoactive peptides. Pure & Applied Chemistry, Vol. 59, No. 3, pp. 317—324.
  9. JOHANNSEN L., ROSENTHAL, R.S., MARTIN, S.A., CADY, A.B., OBAL, Jr. F., GUINAND M., KRUEGER, J.M. (1989). Somnogenic activity of O-acetylated and dimeric muramyl dipeptides. Infection and Immunity, 57(9):2726-2732.

© 2014, Gerbu Biotechnik GmbH Imprint | Terms of Use | Privacy Notice